| Name | Title | Contact Details |
|---|
Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.
Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.
Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developed. We seamlessly integrate our capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated
Abraxis Oncology is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.